Rhythm Pharmaceuticals, Inc.
- RYTM
- NASDAQ
- Biotechnology
- Rare Genetic Obesity
- MC4 Agonist (IMCIVREE)
$90.20
Today +2.23%Quote Oct 20, 2026, 08:00 PM UTC
−8.73%over the last month
Max drawdown −13.2%From 1-month high −9.1%3 months −13.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
414
Market value
$6.21B
Quote Oct 20
Floor
$89.93
0.3% below price
Resistance
$93.70
3.9% above price
Price vs analyst targets
22 analysts
Lowest target
$120.00Highest target
$160.00
$120.00Highest target
$160.00
- Price $90.20
- Average target $144.43
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 60% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RYTMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free